An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity.
about
Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosaVaccines for Pseudomonas aeruginosa: a long and winding roadV-antigen homologs in pathogenic gram-negative bacteriaAssociation between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: a reviewModified needle-tip PcrV proteins reveal distinct phenotypes relevant to the control of type III secretion and intoxication by Pseudomonas aeruginosaA novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models.Multi-Functional Characteristics of the Pseudomonas aeruginosa Type III Needle-Tip Protein, PcrV; Comparison to Orthologs in other Gram-negative BacteriaBeyond CDR-grafting: Structure-guided humanization of framework and CDR regions of an anti-myostatin antibody.Mutations in the Pseudomonas aeruginosa needle protein gene pscF confer resistance to phenoxyacetamide inhibitors of the type III secretion system.Postgenomic strategies in antibacterial drug discovery.Computational design of a CNT carrier for a high affinity bispecific anti-HER2 antibody based on trastuzumab and pertuzumab Fabs.Frontier of therapeutic antibody discovery: The challenges and how to face them.The molecular mechanism of acute lung injury caused by Pseudomonas aeruginosa: from bacterial pathogenesis to host responseThe anti-Pseudomonas aeruginosa antibody Panobacumab is efficacious on acute pneumonia in neutropenic mice and has additive effects with meropenem.High Throughput Combinatorial Formatting of PcrV Nanobodies for Efficient Potency ImprovementNovel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.Pseudomonas aeruginosa Bacteremic Patients Exhibit Nonprotective Antibody Titers Against Therapeutic Antibody Targets PcrV and Psl Exopolysaccharide.In vitro and in vivo properties of a fully human IgG1 monoclonal antibody that combats multidrug resistant Pseudomonas aeruginosa.The type III secretion system of Pseudomonas aeruginosa: infection by injection.Candida albicans airway exposure primes the lung innate immune response against Pseudomonas aeruginosa infection through innate lymphoid cell recruitment and interleukin-22-associated mucosal responseTreatment options for multidrug-resistant nonfermenters.Recent developments for Pseudomonas vaccines.Will new antimicrobials overcome resistance among Gram-negatives?Novel therapeutic strategies to counter Pseudomonas aeruginosa infections.The post-antibiotic era: promising developments in the therapy of infectious diseases.New perspectives in the management of Pseudomonas aeruginosa infections.Investigational drugs in phase I and phase II clincial trials for the treatment of hospital-acquired pneumonia.Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance.Efficacy comparison of adjuvants in PcrV vaccine against Pseudomonas aeruginosa pneumonia.The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.Epidemiological analysis of serum anti-Pseudomonas aeruginosa PcrV titers in adults.Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa.Therapeutic antibodies and infectious diseases, Tours, France, November 20-22, 2012.Antimicrobial targets localize to the extracellular vesicle-associated proteome of Pseudomonas aeruginosa grown in a biofilm.PcrV antibody-antibiotic combination improves survival in Pseudomonas aeruginosa-infected mice.The best defense is a good (Protease) offense: How Pseudomonas aeruginosa evades mucosal immunity in the lung.
P2860
Q24612271-91847C2A-E0AD-47A3-BB62-7592E4366E6AQ26852817-6E1D96D4-6867-4BAB-8B58-0C4D11A5658CQ27008415-50EC6905-5327-460F-B2F2-5183DDFEFB2FQ27013824-B2E37621-128D-443E-88AB-4BB2F04DDB7FQ28492629-CF9B3082-28BA-42FA-A73F-3BC0524F293BQ30408273-E47DE064-4DB2-4808-8FF0-5BFA153E49C8Q30431366-7AA5790D-0C1B-42B0-86CD-419CC0167608Q31814859-0C2FB601-76C9-41A1-96EA-4C1B6B4D4FCEQ33622815-BBC3172B-D9C5-4311-B3CA-DAF06F8BE0A1Q33745572-FE938242-2575-4C79-A48C-08A422D7D4DEQ34473476-2D7BB89D-9598-4A0D-BDD7-D53687BA7107Q34527769-B7CE1E73-9B9F-48E2-AEBB-45DCDAF9F4F8Q34711734-C8827E10-2713-4B46-8B0C-7E68358ECE8AQ34984415-DFA3EC3F-D0A8-42A6-A72D-5A62505ED994Q36029891-53BE98FE-951F-43FC-A53E-6DECC2A265B8Q36288672-EB5FB1C2-0F34-4A8F-8D92-6213A77D8D5EQ36487854-FD25570B-40B6-4369-9A20-B860B59D5D56Q36613653-40F56382-CA8D-47E6-A9DA-955218709846Q37397923-0889DA94-DE87-45C9-BD14-58CA0A377557Q37548220-81CC0C75-2B6C-4539-A155-CAE08B9EAEFDQ37700555-C5B485FF-579A-47A1-B218-01010D28E532Q37937369-E4E6D217-B347-4CC6-A019-D1C0A6ABE218Q37942654-AA19689C-E59E-4134-9F08-98CE1EB4546BQ37984505-8AE9D9A9-7945-4F00-8DC0-1C698FA26962Q38106970-BC63EA7C-A33A-429F-A43F-64B628173D6AQ38243221-38C819EE-5A83-4063-AF4E-A2AE2F53D839Q38783043-B2AC1E6F-9D56-4D78-BB40-80C92A03D18DQ39197564-E5133500-4BC3-48E8-8791-6E2F6D588AE5Q40267074-32A8E17E-1C30-443A-98CC-1906E1EA63F0Q40601021-98A67781-E0E8-4BF8-A6E5-2E8ABD0E4F7DQ40860257-483EE130-79FD-4B37-9ABD-431468B29F7EQ41380601-EA5D9ABA-CA9F-4E3F-AF89-5BAB41F83A45Q42846265-2212E2F7-C419-4F71-8ACF-F867B814C05FQ42859154-861B7301-3C3A-4030-98C9-DF47C09014EAQ43472217-80C98EFE-22F0-4A9B-970C-5874B39DDD81Q46470522-131D98CE-B863-42B5-81A1-6F11C68AB31E
P2860
An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
An engineered human antibody f ...... potent antibacterial activity.
@en
An engineered human antibody f ...... potent antibacterial activity.
@nl
type
label
An engineered human antibody f ...... potent antibacterial activity.
@en
An engineered human antibody f ...... potent antibacterial activity.
@nl
prefLabel
An engineered human antibody f ...... potent antibacterial activity.
@en
An engineered human antibody f ...... potent antibacterial activity.
@nl
P2093
P2860
P356
P1476
An engineered human antibody f ...... potent antibacterial activity.
@en
P2093
Christopher Bebbington
David Martinez
Geoffrey Yarranton
Jeanine P Wiener-Kronish
Kenneth Luehrsen
Peter Flynn
Teiji Sawa
P2860
P304
P356
10.1128/IAI.00815-08
P407
P577
2008-12-22T00:00:00Z